Aldurazyme, administered once-weekly, has been approved in the US and in 15 countries of the European Union for long-term enzyme replacement therapy in patients with a confirmed diagnosis of MPS I, to treat the non-neurological manifestations of the disease. Aldurazyme was developed by BioMarin and Genzyme under a joint venture agreement that assigns commercial manufacturing responsibilities to BioMarin, and worldwide sales and marketing responsibilities to Genzyme.
Additional information can be obtained at www.aldurazyme.com or by contacting Genzyme at 800-745-4447.
Elaprase is a long term enzyme replacement therapy for patients with a confirmed diagnosis of MPS II which has been approved for use in the US, Canada, and many countries in Europe. Elaprase was developed and is produced by Shire Human Genetic Therapies (formerly TKT), and is given as weekly infusions to replace the missing enzyme that Hunter syndrome patients fail to produce in sufficient quantities.
Additional information can be obtained at www.shire.com or by contacting OnePathSM
toll free 866-888-0660. OnePath provides assistance with insurance, product access, treatment centers and education about Elaprase and MPS II.
Naglazyme is the enzyme replacement therapy for individuals with a confirmed diagnosis of MPS VI and has been approved for use in the US and in many European countries. Developed and produced by BioMarin Pharmaceutical, Inc, Naglazyme has been shown to improve walking and stair-climbing capacity.
For more information, please contact BioMarin Patient and Physician Support (BPPS) at email@example.com or 866-906-6100